A5101454631- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Vaccine Coverage and Hesitancy
- Hepatitis C virus research
- Viral gastroenteritis research and epidemiology
- Participatory Visual Research Methods
- Renal cell carcinoma treatment
- Influenza Virus Research Studies
- Animal Disease Management and Epidemiology
- Academic and Historical Perspectives in Psychology
- Economic and Financial Impacts of Cancer
- COVID-19 epidemiological studies
- COVID-19 Pandemic Impacts
- Immune Cell Function and Interaction
- Social Policy and Reform Studies
- Hepatitis B Virus Studies
- Philosophy, Ethics, and Existentialism
- Psychotherapy Techniques and Applications
- Social Representations and Identity
- Gender, Labor, and Family Dynamics
- Systemic Lupus Erythematosus Research
- Educational Philosophies and Pedagogies
- Transactional Analysis in Psychotherapy
ViiV Healthcare (United Kingdom)
2015-2025
London School of Hygiene & Tropical Medicine
2021-2024
Paris School of Economics
2020-2024
The University of Texas Southwestern Medical Center
2024
Southwestern Medical Center
2024
Bristol-Myers Squibb (United Kingdom)
2017-2024
IZA - Institute of Labor Economics
2020-2024
Centre International de Recherche en Infectiologie
2024
Université Claude Bernard Lyon 1
2024
Nagasaki University
2024
The COVID-19 pandemic has led many governments to implement lockdowns. While lockdowns may help contain the spread of virus, they result in substantial damage population well-being. We use Google Trends data test whether implemented Europe and America changes well-being related topic search terms. Using differences-in-differences a regression discontinuity design evaluate causal effects lockdown, we find increase intensity for boredom US. also found significant searches loneliness, worry...
Background:The efficacy of dolutegravir (DTG) has been demonstrated in 5 randomized studies integrase inhibitor (INI)–naive adult populations. To date, a detailed safety review DTG not provided the literature. Objective: describe and tolerability profile adults based on randomized, controlled trials comparison with drugs 3 major antiretroviral (ARV) classes. Methods: Safety data from phase IIb/III/IIIb ART-naive ART-experienced, INI-naive were integrated. Results: In 4 (SPRING-1, SPRING-2,...
Exposure to infected poultry is a suspected cause of avian influenza (H5N1) virus infections in humans. We detected infectious droplets and aerosols during laboratory-simulated processing asymptomatic chickens with human- (clades 1 2.2.1) avian- 1.1, 2.2, 2.1) origin H5N1 viruses. fewer airborne particles simulated ducks. Influenza virus-naive ferrets exposed the air space which virus-infected were processed became died, suggesting that slaughter an efficient source can infect birds mammals....
Abstract Background Persistent LLV (40-1000 c/mL) is associated with virologic failure, drug resistance and increased risk of inflammation may impact morbidity mortality. FTR (prodrug the first-in-class attachment inhibitor temsavir) indicated other antiretrovirals (ARVs) for heavily treatment-experienced individuals MDR HIV-1 unable to construct suppressive regimens. BRIGHTE participants (pts) did not have stop due LLV. We describe outcomes inflammatory biomarkers through Week 192 in pts...
Abstract Background Constructing suppressive regimens in individuals with MDR HIV-1 can be challenging. We assessed populations limited ART options the BRIGHTE study using FTR-based and VIKING-3 DTG-based regimens. Methods was a phase 3 (N=371; Randomized Cohort [RC], n=272; Non-randomized Cohort, n=99) adults failing current (HIV-1 RNA > 400 c/mL) ≤ 2 fully active approved ARVs. Participants (pts) 1 or ARVs entered RC received open-label FTR + optimized background therapy (OBT) after...
Multi-class resistance, intolerance, and drug-drug interactions can result in unique antiretroviral (ART) combinations for heavily treatment-experienced (HTE) people living with HIV (PLWH). We aimed to compare clinical outcomes between HTE non-HTE PLWH.Eligible ART-experienced PLWH care the OPERA® Cohort were identified a cross-sectional manner on December 31, 2016 observed from date of initiation ART regimen taken until loss follow up, death, study end (December 2018), or becoming (non-HTE...
The aim of this study was to evaluate the efficacy maraviroc along with darunavir/ritonavir, all once daily, for treatment antiretroviral-naive HIV-1 infected individuals.MODERN a multicentre, double-blind, noninferiority, phase III in infected, adults plasma RNA at least 1000 copies/ml and no evidence reduced susceptibility drugs.At screening, participants were randomized 1 : undergo either genotypic or phenotypic tropism testing. Participants CCR5-tropic receive 150 mg daily...
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted sustained rates of virologic suppression through 96 weeks. HIV-1 RNA <40 copies/mL was achieved 163/272 (60%) Randomized Cohort (RC) participants (with 1 or 2 remaining approved fully active antiretrovirals) and 37/99 (37%) Non-randomized (NRC) 0 antiretrovirals). Here we report genotypic phenotypic analyses samples from 63/272...
Background. Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)–infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is potential alternative component those with R5-tropic virus. Methods. The Switch Study randomized, multicenter, 96-week, open-label switch study HIV type 1–infected adults virus, on...
Although antiretroviral treatments have improved survival of persons living with HIV, their long-term use may limit available drug options. We estimated the prevalence heavily treatment-experienced (HTE) status and potential clinical consequences becoming HTE.EuroSIDA, a European multicenter prospective cohort study.A composite definition for HTE was developed, based on estimates resistance prior exposure to specific regimens. Risks progressing outcomes were assessed by Poisson regression,...
Efficacy and safety of the attachment inhibitor fostemsavir + optimized background therapy (OBT) were evaluated through 48 96 weeks in phase 3 BRIGHTE trial heavily treatment-experienced (HTE) adults failing their current antiretroviral regimen. Here, we report 240-week efficacy OBT with multidrug-resistant human immunodeficiency virus (HIV)-1 BRIGHTE. Heavily regimen entered randomized cohort (RC; 1–2 fully active antiretrovirals available) or non-randomized (NRC; no received open-label...
The purpose of this work was to evaluate the performance CoVarScan, a multiplex fragment analysis approach, in identifying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Omicron lineage rapidly and accurately. ability identify with high fidelity low turnaround time is important both epidemiologically clinically for pandemic monitoring therapeutic monoclonal antibody (mAb) selection. Currently, gold-standard test task whole-genome sequencing (WGS), which prohibitively...
Fostemsavir is a prodrug of first-in-class HIV-1 attachment inhibitor, temsavir, that binds to gp120 and blocks the host-cell CD4 receptor, preventing entry infection target cell. Previous studies using limited number clinical isolates showed there was intrinsic variability in their susceptibility temsavir.Here, an analysis performed all analysed Monogram Biosciences PhenoSense® Entry assay as part development programme.In total, 1337 individual envelopes encompassing 20 different subtypes...
Abstract Background As the population of people with HIV ages, concerns over managing age-related comorbidities, polypharmacy, immune recovery, and drug-drug interactions while maintaining viral suppression have arisen. We present pooled TANGO SALSA efficacy safety results dichotomized by age (< 50 ≥ years). Methods Week 48 data from open-label phase 3 trials evaluating switch to once-daily dolutegravir/lamivudine (DTG/3TC) fixed-dose combination vs continuing current antiretroviral...